Ftse Mib
34.615,05
1,17%
DAX
18.407,07
1,33%
S&P 500
5.564,41
1,08%
NASDAQ
18.007,57
1,58%
Bitcoin
67.391,03
-0,32%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ XTL Biopharmaceuticals Ltd (XTLB) XTL Biopharmaceuticals Ltd (XTLB) Notizie

XTLB

XTL Biopharmaceuticals (XTLB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XTLB
DataOraFonteTitoloSimboloCompagnia
22/07/202422:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415:15GlobeNewswire Inc.XTL Entered Definitive Agreement to Acquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/03/202415:15GlobeNewswire Inc.XTL To Aquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322:00GlobeNewswire Inc.XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322:00GlobeNewswire Inc.XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelNASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/05/202317:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/02/202315:53Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/202223:16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/06/202112:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117:31Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/08/202015:24Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/01/202012:39Edgar (US Regulatory)Amended Report of Foreign Issuer (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/11/201815:09PR Newswire (US)XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/07/201815:09PR Newswire (US)XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
29/05/201823:37PR Newswire (US)XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/03/201822:05Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
28/02/201822:04Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/01/201821:51Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
06/12/201718:08PR Newswire (US)XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing RequirementsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/11/201716:30PR Newswire (US)XTL Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
23/10/201717:23PR Newswire (US)XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing RequirementsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
26/09/201715:23PR Newswire (US)XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/09/201716:24PR Newswire (US)XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's SyndromeNASDAQ:XTLBXTL Biopharmaceuticals Ltd
15/06/201715:38PR Newswire (US)XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/04/201715:50PR Newswire (US)XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of DirectorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/04/201715:10PR Newswire (US)XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s SyndromeNASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/201714:55PR Newswire (US)XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational UpdateNASDAQ:XTLBXTL Biopharmaceuticals Ltd
29/03/201723:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
22/03/201714:22PR Newswire (US)XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing InvestorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/03/201718:40PR Newswire (US)XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing InvestorsNASDAQ:XTLBXTL Biopharmaceuticals Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XTLB

La tua Cronologia

NASDAQ
MLVF
Malvern Bancorp
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network